Traw Pharma did a capital raise yesterday16 Apr 2026 08:17
For the Hvivo HCT..it seems they were very impressed with the Cidara HCT that Hvivo did and are going down the same route
Gross Proceeds: Approximately $10 million upfront.
Shares Issued: 5,982,919 shares of common stock (or pre-funded warrants).
Purchase Price: $1.6730 per share, an at-the-market price under Nasdaq rules.
Milestone-Based Warrants ($50 Million Potential)
The remaining $50 million is accessible through three series of warrants, each with an exercise price of $1.6730:
Series A (~$10M): Exercisable once the UK Medicines and Healthcare products Regulatory Agency (MHRA) approves the human challenge trial.
Series B (~$10M): Exercisable following shareholder approval and the announcement of data from the influenza challenge trial.
Series C (~$30M): A three-year warrant exercisable following shareholder approval.
Strategic Use of Proceeds
Influenza Program: Funds are primarily allocated to advance tivoxavir marboxil into a Phase 2a human challenge trial in the UK.
Clinical Partner: Traws recently signed a contract with hVIVO to conduct this trial.
Cash Runway: If warrants are fully exercised, the capital is expected to support operations into Q1 2027.
The financing was led by Sirenia Capital Management LP, with participation from various institutional and accredited investors. Cantor Fitzgerald & Co. served as the lead placement agent.
Traws Pharma raises USD 60m in private placement financing - AllSci
AllSci
Traws Pharma Reports Full Year 2025 Results and Provides ...
markets.businessinsider.com
Sign In
Follow the stocks
